Sudeep Pharma posts record Q2 FY27: revenue up 21% to Rs 196.7 crore, EBITDA up 32%; Nandesari gets FDA nod, Dahej battery plant on track
Q2 FY27 revenue up 21% to Rs 196.7 crore, EBITDA up 32% to Rs 73.2 crore at 37.2% margin; PAT up 11% to Rs 51.8 crore.
By ScoutQuest · · 1 min read
- Revenue
- Q2 FY27 revenue from operations was Rs 196.7 crore, up 21% YoY
- EBITDA
- EBITDA Rs 73.2 crore, up 32%, with margin at 37.2% versus 34.1%
- PAT
- PAT rose 11% to Rs 51.8 crore
- Period
- Q2 & H1 FY27
- Positioning
- The company describes itself as a technology-led specialty ingredients manufacturer serving the pharmaceutical, food and nutrition industry, a leading player in excipients and mineral actives, building battery materials capabilities.
📉 Q2 FY27 revenue from operations was Rs 196.7 crore, up 21% YoY, and EBITDA Rs 73.2 crore, up 32%, with margin at 37.2% versus 34.1%. PAT rose 11% to Rs 51.8 crore, slower than EBITDA as other income fell and tax rose. H1 FY27 revenue was Rs 355.0 crore, up 23%, and PAT Rs 92.4 crore, up 18%.
💰 The company calls itself a technology-led specialty ingredients maker; PFN contributed 72% of quarterly revenue and Specialty Ingredients 28%. Net working capital days have risen to 215 in H1 FY27 from 107 in FY23, and RoCE has eased to 22.40% from 41.46% in FY24.
🏭 Management states the Nandesari greenfield facility (51,200 MT) received FDA approval and expects commercial supplies to start in H2 FY27. The company says Dahej Phase 1 battery-grade iron phosphate (25,000 MTPA) is targeted for completion by March 2027 with operations from April 2027, with a 105,000 MT target and a further 100,000 MT under evaluation.
🎯 As backing for the battery plan, the presentation lists 46 active customers, 28 product approvals, 0 sample rejections and 8 MOUs, and says binding offtake agreements are targeted to be signed by Q4 FY27.
Also from Sudeep Pharma
Earnings call transcript: record quarterly revenue and EBITDA, segment-wise outlook outlined
3 Nov 2026
Sudeep Pharma uploads audio recording of earnings call held 29 October 2026
29 Oct 2026
Sudeep Pharma reported strong EBITDA growth of around 31% year-on-year
29 Oct 2026
More numbers
- Revenue from operations, Q2FY27196.7 (Rs. Crs)
- Revenue growth YoY, Q2FY2721%
- EBITDA, Q2FY2773.2 (Rs. Crs)
- EBITDA margin, Q2FY2737.2%
- Profit after tax, Q2FY2751.8 (Rs. Crs)
- Revenue from operations, H1FY27355.0 (Rs. Crs)
- Profit after tax, H1FY2792.4 (Rs. Crs)
- Revenue from operations, FY26642.3 (Rs. Crs)
- Profit after tax, FY26174.3 (Rs. Crs)
- Net working capital days, H1FY27215
- RoCE, H1FY2722.40%
- Net debt, H1FY2772.5 (Rs. Cr.)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.